ArticleFrontiers in oncology2021

Case Report: Combined CDK4/6 and MEK Inhibition in Refractory CDKN2A and NRAS Mutant Melanoma.

Andrea Forschner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.